Anti-inflammatory potential of the probiotic dietary supplement Lactibiane Tolérance: In vitro and in vivo considerations

Clinical Nutrition

Volumn 25, Issue 6, 2006, Pages 994-1003

  Drouault Holowacz, Sophie ^a   Foligné, Benoît ^b   Dennin, Véronique ^b   Goudercourt, Denise ^b   Terpend, Kathleen ^a   Burckel, André ^a   Pot, Bruno ^b  

^a PiLeJe   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Cytokines; Experimental colitis; Lactibiane Tol rance; Probiotics

Indexed keywords

LACTIBIANE TOLERANCE; LACTIC ACID; PROBIOTIC AGENT; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIFIDOBACTERIUM ANIMALIS; CELL STIMULATION; COLITIS; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE RELEASE; DIET SUPPLEMENTATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS SALIVARIUS; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SCORING SYSTEM; SYMPTOM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIFIDOBACTERIUM; CELLS, CULTURED; COLITIS; CYTOKINES; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LACTOBACILLUS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; PROBIOTICS; RANDOM ALLOCATION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRINITROBENZENESULFONIC ACID;

EID: 33751016017     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2006.03.006     Document Type: Article

References (44)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115 (1998) 182-205
2. McKay D.M. Intestinal inflammation and the gut microflora. Can J Gastroenterol 13 (1999) 509-516
3. Podolsky D.K. The current future understanding of inflammatory bowel disease. Best Pract Res Clin Gastroenterol 16 (2002) 933-943
4. Thompson-Chagoyan O.C., Maldonado J., and Gil A. Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin Nutr 24 (2005) 339-352
5. FAO/OMS Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report of a Joint FAO/WHO Expert Consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Córdoba, Argentina, 1-4 October 2001.
6. Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 17 (2003) 755-773
7. Servin A.L. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 28 (2004) 405-440
8. Fedorak R.N., and Madsen K.L. Probiotics and prebiotics in gastrointestinal disorders. Curr Opin Gastroenterol 20 (2004) 146-155
9. Gionchetti P., Rizzello F., Helwig U., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124 (2003) 1202-1209
10. Kruis W. Review article: antibiotics and probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 20 Suppl 4 (2004) 75-78
11. Gionchetti P., Amadini C., Rizzello F., et al. Probiotics-role in inflammatory bowel disease. Dig Liver Dis 34 Suppl. 2 (2002) S58-S62
12. Hart A.L., Stagg A.J., and Kamm M.A. Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 36 (2003) 111-119
13. Madsen K.L., Doyle J.S., Jewell L.D., Tavernini M.M., and Fedorak R.N. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116 (1999) 1107-1114
14. McCarthy J., O'Mahony L., O'Callaghan L., et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52 (2003) 975-980
15. Shanahan F. Probiotics and inflammatory bowel disease: from fads and fantasy to facts and future. Br J Nutr 88 Suppl. 1 (2002) S5-S9
16. Chapat L., Chemin K., Dubois B., Bourdet-Sicard R., and Kaiserlian D. Lactobacillus casei reduces CD8+ T cell-mediated skin inflammation. Eur J Immunol 34 (2004) 2520-2528
17. Maassen C.B., Boersma W.J., van Holten-Neelen C., Claassen E., and Laman J.D. Growth phase of orally administered Lactobacillus strains differentially affects IgG1/IgG2a ratio for soluble antigens: implications for vaccine development. Vaccine 21 (2003) 2751-2757
18. Maassen C.B., van Holten-Neelen C., Balk F., et al. Strain-dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine 18 (2000) 2613-2623
19. Perdigon G., Maldonado Galdeano C., Valdez J.C., and Medici M. Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr 56 Suppl. 4 (2002) S21-S26
20. Schultz M., Veltkamp C., Dieleman L.A., et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis 8 (2002) 71-80
21. Di Giacinto C., Marinaro M., Sanchez M., Strober W., and Boirivant M. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol 174 (2005) 3237-3246
22. Mimura T., Rizzello F., Helwig U., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53 (2004) 108-114
23. Rachmilewitz D., Katakura K., Karmeli F., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126 (2004) 520-528
24. Mahida Y.R., and Rolfe V.E. Host-bacterial interactions in inflammatory bowel disease. Clin Sci (London) 107 (2004) 331-341
25. Foligne B., Grangette C., and Pot B. Probiotics in IBD: mucosal and systemic routes of administration may promote similar effects. Gut 54 (2005) 727-728
26. Wallace J.L., MacNaughton W.K., Morris G.P., and Beck P.L. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96 (1998) 29-36
27. Desreumaux P., Dubuquoy L., Nutten S., et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 193 (2001) 827-838
28. Ameho C.K., Adjei A.A., Harrison E.K., et al. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 41 (1997) 487-493
29. Foligné B., Nutten S., Steidler L., et al. Recommandations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: Technical and microbiological aspects. Dig Dis Sci 51 (2006) 390-400
30. Dieleman L.A., Goerres M.S., Arends A., et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 52 (2003) 370-376
31. Mercenier A., Pavan S., and Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr Pharm Des 9 (2003) 175-191
32. Huhn R.D., Radwanski E., O'Connell S.M., et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 87 (1996) 699-705
33. Chernoff A.E., Granowitz E.V., Shapiro L., et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154 (1995) 5492-5499
34. van Deventer S.J., Elson C.O., and Fedorak R.N. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 113 (1997) 383-389
35. Rennick D., Davidson N., and Berg D. Interleukin-10 gene knock-out mice: a model of chronic inflammation. Clin Immunol Immunopathol 76 (1995) S174-S178
36. Davidson N.J., Leach M.W., Fort M.M., et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 184 (1996) 241-251
37. Kuhn R., Lohler J., Rennick D., Rajewsky K., and Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75 (1993) 263-274
38. Steidler L., Hans W., Schotte L., et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289 (2000) 1352-1355
39. Schotte L., Steidler L., Vandekerckhove J., and Remaut E. Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb Technol 27 (2000) 761-765
40. D'Andrea A., Aste-Amezaga M., Valiante N.M., Ma X., Kubin M., and Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 178 (1993) 1041-1048
41. Trembleau S., Germann T., Gately M K., and Adorini L. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 16 (1995) 383-386
42. Peran L., Camuesco D., Comalada M., et al. Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. World J Gastroenterol 11 (2005) 5185-5192
43. Mercenier A., Hols P., Roussel Y., et al. Screening and construction of probiotic strains with enhanced protective properties against intestinal disorders. Microb Ecol Health Dis 16 Suppl. (2004) 86-95
44. Hart A.L., Lammers K., Brigidi P., et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53 (2004) 1602-1609